ReviewCurrent oncology reports2026
Unraveling the Mechanisms of Chemoresistance in Gastric Cancer: Insights and Emerging Research Strategies.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewGastric cancer (GC) is a leading cause of cancer death globally. Platinum‑based drugs, fluoropyrimidines, and docetaxel are standard for advanced disease, but intrinsic and acquired resistance limit the efficacy. This review summarizes chemoresistance mechanisms, focusing on the roles of various cell death pathways in GC chemoresistance, as well as the involvement of non-coding RNAs (ncRNAs) in modulating drug resistance through multiple regulatory mechanisms. We also describe models for establishing resistant cell lines (stepwise dose escalation, high-dose intermittent pulse selection, gene transfection). RECENT
findingsEmerging evidence has identified intricate crosstalk among apoptosis, autophagy, and ferroptosis in chemoresistant GC cells. Aberrant expression of Bcl‑2 family members, protective autophagic flux, and suppression of ferroptosis (e.g., via SLC7A11/GPX4) are key drivers. Concurrently, ncRNAs particularly microRNAs, long non‑coding RNAs, and circular RNAs have been shown to modulate resistance by targeting death‑related genes, altering drug efflux, or reprogramming the tumor microenvironment. Preclinical agents that modulate ferroptosis or ncRNA expression demonstrate promising chemosensitizing effects. Collectively, the interplay between cell death pathways and the ncRNA regulatory networks profoundly influences chemoresistance in GC. Deciphering these mechanisms offers a theoretical basis for developing biomarkers and combination strategies that overcome resistance, ultimately improving patient outcomes.
Indexed as
Identifiers
42804038What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.